Advertisement

Drug Safety

pp 1–9 | Cite as

Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case–Control Study

  • Wiebke Schäfer
  • Christina Princk
  • Bianca Kollhorst
  • Tania SchinkEmail author
Original Research Article

Abstract

Background and Purpose

Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed in the elderly due to a more favorable risk profile than other antidepressants (ADs). However, SSRIs are associated with an increased risk of gastrointestinal bleeding, while evidence on the risk of hemorrhagic stroke (HS) is limited. Therefore, we compared the risk of HS associated with the use of ADs in the elderly.

Methods

Based on data from the German Pharmacoepidemiological Research Database (GePaRD), a case–control study matched on age, sex, and health insurance provider, nested in a cohort of incident users of ADs ≥ 65 years of age was performed. Cases were identified from hospital discharge diagnoses, and exposure was identified from outpatient prescriptions. Multivariable conditional logistic regression was used to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs).

Results

Based on 4059 cases and 40,590 controls, an increased risk of HS was found in current use of SSRIs (OR 1.39, 95% CI 1.22–1.58), selective serotonin and noradrenaline reuptake inhibitors (1.69, 1.35–2.11), noradrenergic and specific serotonergic ADs (1.44, 1.22–1.69), and noradrenaline reuptake inhibitors (3.81, 1.54–9.43) compared with tri- and tetracyclic antidepressants. An increased risk of HS was seen in patients with a high baseline risk of bleeding and in patients with depression. The risk of HS varied between individual ADs.

Conclusion

Our study shows that the use of medications inhibiting serotonin and/or noradrenaline reuptake increases the risk of HS in patients aged 65 years and older and that the risk varies across individual ADs.

Notes

Acknowledgements

The authors would like to thank all SHIs who provided data for this study, namely AOK Bremen/Bremerhaven, DAK-Gesundheit, hkk Krankenkasse, and Die Techniker (TK). The authors would further would like to thank Franziska von Mandelsloh and Nadine Schlie for their help in developing the outcome definitions and defining potential confounding factors, as well as Marieke Niemeyer and Inga Schaffer for statistical programming of the matched cohort.

Compliance with Ethical Standards

Conflicts of Interest

Wiebke Schäfer, Bianca Kollhorst, and Tania Schink are employees of the Leibniz Institute for Prevention Research and Epidemiology – BIPS. Unrelated to this study, BIPS occasionally conducts studies financed by the pharmaceutical industry. Almost exclusively, these are post-authorization safety studies (PASS) requested by health authorities. The studies and the resulting publications are not influenced by the pharmaceutical industry. Christina Princk is currently an employee at the Governmental Institute of Public Health of Lower Saxony, Hanover, Germany, and has no conflicts of interest that are directly relevant to the content of this study.

Ethical Approval

In Germany, the utilization of health insurance data for scientific research is regulated by the Code of Social Law. All involved SHIs, the German Federal (Social) Insurance, and the Senator for Science, Health and Consumer Protection in Bremen as their responsible authorities approved the use of the data for this study. Informed consent for studies based on the GePaRD is not required by law, and, according to the Ethics Committee of the University of Bremen, these studies are exempt from Institutional Review Board review.

Funding

No sources of funding were used to assist in the preparation of this study.

Supplementary material

40264_2019_837_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 21 kb)
40264_2019_837_MOESM2_ESM.docx (18 kb)
Supplementary material 2 (DOCX 19 kb)
40264_2019_837_MOESM3_ESM.docx (18 kb)
Supplementary material 3 (DOCX 18 kb)

References

  1. 1.
    Cecilio Á, Francisco LM, Pilar GG, Silvia GR. Risk–benefit analysis of antidepressant drug treatment in the elderly. Psychogeriatrics. 2014;14(4):261–8.CrossRefGoogle Scholar
  2. 2.
    American Geriatrics Society Beers Criteria Update Expert Panel. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRefGoogle Scholar
  3. 3.
    O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. Stopp/start criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.CrossRefGoogle Scholar
  4. 4.
    de Abajo FJ, Alberto L, Rodríguez G, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106–9.CrossRefGoogle Scholar
  5. 5.
    de Abajo FJ, Montero D, Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006;98(3):304–10.CrossRefGoogle Scholar
  6. 6.
    Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164(21):2367–70.CrossRefGoogle Scholar
  7. 7.
    Eschenfelder CC, Zeller JA, Stingele R. Schlaganfall—ursachen und klassifikation. Hämostaseologie. 2006;26(4):298–308.CrossRefGoogle Scholar
  8. 8.
    Zahuranec DB, Lisabeth LD, Sanchez BN, Smith MA, Brown DL, Garcia NM, et al. Intracerebral hemorrhage mortality is not changing despite declining incidence. Neurology. 2014;82(24):2180–6.CrossRefGoogle Scholar
  9. 9.
    Lekander I, Willers C, von Euler M, Lilja M, Sunnerhagen KS, Pessah-Rasmussen H, et al. Relationship between functional disability and costs one and two years post stroke. PLoS One. 2017;12(4):e0174861.CrossRefGoogle Scholar
  10. 10.
    Douglas I, Smeeth L, Irvine D. The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. Br J Clin Pharmacol. 2010;71:115–20.Google Scholar
  11. 11.
    Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38:3049–51.CrossRefGoogle Scholar
  12. 12.
    Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the women’s health initiative study. Arch Intern Med. 2009;169(22):2128–39.CrossRefGoogle Scholar
  13. 13.
    Bak S, Tsiropoulos I, Kjærsgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin reuptake inhibitors and the risk of stroke a population-based case-control study. Stroke. 2002;33:1465–73.CrossRefGoogle Scholar
  14. 14.
    Chen Y, Guo JJ, Li H, Wulsin L, Patel NC. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Ann Pharmacother. 2008;42(2):177–84.CrossRefGoogle Scholar
  15. 15.
    de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol. 2000;50:43–7.CrossRefGoogle Scholar
  16. 16.
    Renoux C, Vahey S, Dell’Aniello S, Boivin J. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. 2017;74(2):173–80.CrossRefGoogle Scholar
  17. 17.
    Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. CNS Drugs. 2018;32(4):321–34.CrossRefGoogle Scholar
  18. 18.
    Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HG, Egberts TC. Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther. 2011;89(1):89–96.CrossRefGoogle Scholar
  19. 19.
    Wu CS, Wang SC, Cheng YC, Gau SS. Association of cerebrovascular events with antidepressant use: a case-crossover study. The American journal of psychiatry. 2011;168(5):511–21.CrossRefGoogle Scholar
  20. 20.
    Ohlmeier C, Langner I, Garbe E, Riedel O. Validating mortality in the german pharmacoepidemiological research database (gepard) against a mortality registry. Pharmacoepidemiol Drug Saf. 2016;25(7):778–84.CrossRefGoogle Scholar
  21. 21.
    Jobski K, Kollhorst B, Garbe E, Schink T. The risk of ischemic cardio- and cerebrovascular events associated with oxycodone–naloxone and other extended-release high-potency opioids: a nested case–control study. Drug Saf. 2017;40(6):505–15.CrossRefGoogle Scholar
  22. 22.
    Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E. Characteristics and drug use patterns of older antidepressant initiators in germany. Eur J Clin Pharmacol. 2017;73(1):105–13.CrossRefGoogle Scholar
  23. 23.
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.CrossRefGoogle Scholar
  24. 24.
    Rothman KJ, Greenland S, Lash TL. Case-control studies. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. Philadelphia: Lippincott Williams & Wilkens; 2008. p. 111–27.Google Scholar
  25. 25.
    Schmedt N, Jobski K, Kollhorst B, Krappweis J, Ruther E, Schink T, et al. Treatment patterns and characteristics of older antipsychotic users in germany. Int Clin Psychopharmacol. 2016;31(3):159–69.CrossRefGoogle Scholar
  26. 26.
    Gardarsdottir H, Souverein PC, Egberts TC, Heerdink ER. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol. 2010;63(4):422–7.CrossRefGoogle Scholar
  27. 27.
    Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–37.CrossRefGoogle Scholar
  28. 28.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefGoogle Scholar
  29. 29.
    Mutschler E, Geisslinger G, Kroemer HK, Menzel S, Ruth P. Mutschler arzneimittelwirkungen. Lehrbuch der pharmakologie, der klinischen pharmakologie und toxikologie. [Mutschler Drug Reactions. Textbook of Pharmacology, Clinical Pharmacology and Toxicology]. Stuttgart: Wissenschaftliche verlagsgesellschaft mbH; 2013.Google Scholar
  30. 30.
    Lee YC, Lin CH, Lin MS, Lu Y, Chang CH, Lin JW. Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events. J Clin Psychiatry. 2016;77(1):e1–7.CrossRefGoogle Scholar
  31. 31.
    Chen Y, Guo JJ, Li H, Wulsin L, Patel NC. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case–control study. Neurology. 2008;42:177–84.Google Scholar
  32. 32.
    Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.CrossRefGoogle Scholar
  33. 33.
    Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med. 2012;172(10):781–8.CrossRefGoogle Scholar
  34. 34.
    Knoll J, Bernheim MLC. Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. Ciba foundation symposium 39—monoamine oxidase and its inhibition. John Wiley & Sons, Ltd; 2008. Pp 135–61.Google Scholar
  35. 35.
    Sandler M. Monoamine oxidase inhibitor efficacy in depression and the “cheese effect”. Psychol Med. 1981;11(3):455–8.CrossRefGoogle Scholar
  36. 36.
    Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47–59.Google Scholar
  37. 37.
    Garbe E, Kreisel SH, Behr S. Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use. Stroke. 2013;44(9):2422–6.CrossRefGoogle Scholar
  38. 38.
    Feigin V, Lawes C, Bennett D, Anderson C. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2:43–53.CrossRefGoogle Scholar
  39. 39.
    Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990–2013: the gbd 2013 study. Neuroepidemiology. 2015;45(3):161–76.CrossRefGoogle Scholar
  40. 40.
    Martini SR, Flaherty ML, Brown WM, Haverbusch M, Comeau ME, Sauerbeck LR, et al. Risk factors for intracerebral hemorrhage differ according to hemorrhage location. Neurology. 2012;79(23):2275–82.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Leibniz Institute for Prevention Research and EpidemiologyBremenGermany

Personalised recommendations